Gena Wang Analyst Performance

Managing Director, Biotech Equity Research at Barclays

Gena Wang is a stock analyst at Barclays focused in the medical sector, covering 33 publicly traded companies. Over the past year, Gena Wang has issued 39 stock ratings, including buy, hold, and sell recommendations. While full access to Gena Wang's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gena Wang's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 143 Last 10 Years
Buy Recommendations: 66.43% 95 Buy Ratings
Companies Covered: 33 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	66.4%	95 ratings
Hold	25.9%	37 ratings
Sell	7.7%	11 ratings

Out of 143 total stock ratings issued by Gena Wang at Barclays, the majority (66.4%) have been Buy recommendations, followed by 25.9% Hold and 7.7% Sell.

Best & Worst Calls

Best Call
0000.0%
CASC
Nov 2016
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
OVAS
Mar 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	33 companies

Gena Wang, an analyst at Barclays, currently covers 33 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 31 companies	93.9%
	Miscellaneous 2 companies	6.1%

Gena Wang of Barclays specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 21 companies	63.6%
PHARMACEUTICAL PREPARATIONS 4 companies	12.1%
MED - DRUGS 3 companies	9.1%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	6.1%
Miscellaneous 2 companies	6.1%
BIOTECHNOLOGY 1 company	3.0%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
CYTK Cytokinetics	10/6/2025	Boost Price Target	$56.97	$82.00	Overweight
KOD Kodiak Sciences	9/25/2025	Upgrade	$15.49	$17.00	Equal Weight
IONS Ionis Pharmaceuticals	9/23/2025	Boost Price Target	$61.36	$82.00	Overweight
IONS Ionis Pharmaceuticals	9/3/2025	Boost Price Target	$60.44	$78.00	Overweight
CYTK Cytokinetics	9/3/2025	Boost Price Target	$47.91	$71.00	Overweight
IONS Ionis Pharmaceuticals	8/22/2025	Boost Price Target	$43.24	$58.00	Overweight
KOD Kodiak Sciences	8/14/2025	Boost Price Target	$8.62	$7.00	Underweight
RNA Avidity Biosciences	8/8/2025	Reiterated Rating	$47.52	$62.00	Overweight
RGNX REGENXBIO	8/8/2025	Lower Price Target	$7.96	$37.00	Overweight
CRSP CRISPR Therapeutics	8/6/2025	Boost Price Target	$54.76	$56.00	Equal Weight
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
BEAM Beam Therapeutics	8/6/2025	Lower Price Target	$17.86	$21.00	Equal Weight
MRNA Moderna	8/4/2025	Lower Price Target	$27.39	$31.00	Equal Weight
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$392.24	$460.00	Overweight
PTCT PTC Therapeutics	7/29/2025	Boost Price Target	$49.02	$46.00	Equal Weight
SRPT Sarepta Therapeutics	7/29/2025	Upgrade	$17.42	$22.00	Equal Weight
SRPT Sarepta Therapeutics	7/28/2025	Downgrade	$12.43		Strong Sell
SRPT Sarepta Therapeutics	7/27/2025	Reiterated Rating	$16.54		Underweight
SRPT Sarepta Therapeutics	7/22/2025	Set Price Target	$13.32	$18.00	Equal Weight
SRPT Sarepta Therapeutics	7/22/2025	Downgrade	$13.61		Underweight
SRPT Sarepta Therapeutics	7/17/2025	Boost Price Target	$22.10	$32.00	Overweight
IONS Ionis Pharmaceuticals	7/1/2025	Upgrade	$39.51	$57.00	Overweight
SRPT Sarepta Therapeutics	6/17/2025	Lower Price Target	$21.72	$29.00	Overweight
RNA Avidity Biosciences	6/10/2025	Boost Price Target	$32.66	$59.00	Overweight
RNA Avidity Biosciences	6/10/2025	Boost Price Target	$32.66	$59.00	Overweight
SLDB Solid Biosciences	5/16/2025	Lower Price Target	$2.87	$10.00	Overweight
SGMO Sangamo Therapeutics	5/14/2025	Lower Price Target	$0.46	$5.00	Overweight
CLLS Cellectis	5/13/2025	Lower Price Target	$1.42	$4.00	Overweight
FDMT 4D Molecular Therapeutics	5/9/2025	Lower Price Target	$3.26	$38.00	Overweight
CRSP CRISPR Therapeutics	5/9/2025	Lower Price Target	$37.20	$42.00	Equal Weight
PTCT PTC Therapeutics	5/8/2025	Lower Price Target	$42.96	$42.00	Equal Weight
BCRX BioCryst Pharmaceuticals	5/7/2025	Boost Price Target	$10.27	$11.00	Equal Weight
BEAM Beam Therapeutics	5/7/2025	Lower Price Target	$15.92	$25.00	Equal Weight
CYTK Cytokinetics	4/24/2025	Initiated Coverage	$38.00	$55.00	Overweight
BLUE bluebird bio	3/31/2025	Lower Price Target	$5.10	$8.00	Overweight
VIR Vir Biotechnology	2/28/2025	Boost Price Target	$8.39	$31.00	Overweight
NTLA Intellia Therapeutics	2/28/2025	Lower Price Target	$10.09	$26.00	Overweight
MRNA Moderna	2/18/2025	Downgrade	$32.99	$45.00	Equal Weight
CRSP CRISPR Therapeutics	2/12/2025	Boost Price Target	$39.62	$56.00	Equal Weight
VRTX Vertex Pharmaceuticals	2/11/2025	Boost Price Target	$460.76	$467.00	Equal Weight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.